Zacks Small Cap Research

IN8bio, Inc (NASDAQ:INAB) reported second quarter 2024 financial results and achievements on August 8th followed a few days later by an update on the INB-100 and INB-200 programs and the anticipated path forward. In addition to showing continued impressive survival duration, IN8bio also shared the anticipated registrational trial design for INB-100 in acute myeloid leukemia (AML). In June, the company presented INB-100 and INB-200 data at the European Hematology Association (EHA) Congress and the American Society of Clinical Oncology (ASCO) Annual Meeting. Other recent highlights include presentation of γδ T cell manufacturing processes at the International Society for Cell & Gene Therapy meeting and participation in investor conferences.